Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.

Zuardi AW.

Rev Bras Psiquiatr. 2008 Sep;30(3):271-80. Review.

2.

Safety and side effects of cannabidiol, a Cannabis sativa constituent.

Bergamaschi MM, Queiroz RH, Zuardi AW, Crippa JA.

Curr Drug Saf. 2011 Sep 1;6(4):237-49. Review.

PMID:
22129319
3.

Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.

Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimarães FS.

Braz J Med Biol Res. 2006 Apr;39(4):421-9. Epub 2006 Apr 3. Review.

4.

Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.

Schier AR, Ribeiro NP, Silva AC, Hallak JE, Crippa JA, Nardi AE, Zuardi AW.

Rev Bras Psiquiatr. 2012 Jun;34 Suppl 1:S104-10. Review. English, Portuguese.

5.

Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders.

Scuderi C, Filippis DD, Iuvone T, Blasio A, Steardo A, Esposito G.

Phytother Res. 2009 May;23(5):597-602. doi: 10.1002/ptr.2625. Review.

PMID:
18844286
6.

Cannabidiol--recent advances.

Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO.

Chem Biodivers. 2007 Aug;4(8):1678-92. Review.

PMID:
17712814
7.

Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects.

Mechoulam R, Hanus L.

Chem Phys Lipids. 2002 Dec 31;121(1-2):35-43. Review.

PMID:
12505688
8.

A systematic review of the antipsychotic properties of cannabidiol in humans.

Iseger TA, Bossong MG.

Schizophr Res. 2015 Mar;162(1-3):153-61. doi: 10.1016/j.schres.2015.01.033. Epub 2015 Feb 7. Review.

PMID:
25667194
9.

Cannabidiol: a promising drug for neurodegenerative disorders?

Iuvone T, Esposito G, De Filippis D, Scuderi C, Steardo L.

CNS Neurosci Ther. 2009 Winter;15(1):65-75. doi: 10.1111/j.1755-5949.2008.00065.x. Review.

PMID:
19228180
10.

A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol.

Russo E, Guy GW.

Med Hypotheses. 2006;66(2):234-46. Epub 2005 Oct 4.

PMID:
16209908
11.

Cannabidiol, neuroprotection and neuropsychiatric disorders.

Campos AC, Fogaça MV, Sonego AB, Guimarães FS.

Pharmacol Res. 2016 Oct;112:119-127. doi: 10.1016/j.phrs.2016.01.033. Epub 2016 Feb 1. Review.

PMID:
26845349
12.

Could cannabidiol be used as an alternative to antipsychotics?

Fakhoury M.

J Psychiatr Res. 2016 Sep;80:14-21. doi: 10.1016/j.jpsychires.2016.05.013. Epub 2016 May 28. Review.

PMID:
27267317
13.

Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects.

Breuer A, Haj CG, Fogaça MV, Gomes FV, Silva NR, Pedrazzi JF, Del Bel EA, Hallak JC, Crippa JA, Zuardi AW, Mechoulam R, Guimarães FS.

PLoS One. 2016 Jul 14;11(7):e0158779. doi: 10.1371/journal.pone.0158779. eCollection 2016. Erratum in: PLoS One. 2016;11(8):e0162087.

14.

Cannabidiol as a potential treatment for psychosis.

Schubart CD, Sommer IE, Fusar-Poli P, de Witte L, Kahn RS, Boks MP.

Eur Neuropsychopharmacol. 2014 Jan;24(1):51-64. doi: 10.1016/j.euroneuro.2013.11.002. Epub 2013 Nov 15. Review.

PMID:
24309088
15.

Neurological Aspects of Medical Use of Cannabidiol.

Mannucci C, Navarra M, Calapai F, Spagnolo EV, Busardò FP, Cas RD, Ippolito FM, Calapai G.

CNS Neurol Disord Drug Targets. 2017;16(5):541-553. doi: 10.2174/1871527316666170413114210. Review.

PMID:
28412918
16.

Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation?

Zlebnik NE, Cheer JF.

Annu Rev Neurosci. 2016 Jul 8;39:1-17. doi: 10.1146/annurev-neuro-070815-014038. Epub 2016 Feb 24. Review.

17.

On the pharmacological properties of Delta9-tetrahydrocannabinol (THC).

Costa B.

Chem Biodivers. 2007 Aug;4(8):1664-77. Review.

PMID:
17712813
18.

Clinical potential of minocycline for schizophrenia.

Miyaoka T.

CNS Neurol Disord Drug Targets. 2008 Oct;7(4):376-81. Review.

PMID:
18991666
19.

Does cannabidiol protect against the negative effects of THC?

Henquet C, Kuepper R.

Br J Psychiatry. 2010 Oct;197(4):259-60. doi: 10.1192/bjp.bp.110.081380.

PMID:
20884945
20.

Cannabidiol: an overview of some pharmacological aspects.

Mechoulam R, Parker LA, Gallily R.

J Clin Pharmacol. 2002 Nov;42(S1):11S-19S. Review.

PMID:
12412831

Supplemental Content

Support Center